Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07734415
Enrolling by invitation Phase 2

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

NCT07734415 · tracked via the Priya Life Science USA tracker
Sponsor
Inmagene LLC
Phase
Phase 2
Started
2026-06-05
Last updated
2026-07-29

Condition(s) studied

Atopic DermatitisAtopic Dermatitis EczemaEczema

Investigational drug(s) / intervention(s)

IMG-007 →

IMG-007: Participants will receive IMG-007 subcutaneously.

Study summary

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203

Primary outcome measure(s)

  • Evaluate the safety of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis — Baseline, Week 44
    Incidence and severity of TEAEs, including treatment-emergent SAEs, AESIs, and AEs leading to discontinuation

Trial sites (23)

FacilityCityRegionStatus
Inmagene Site 1 Lancaster California
Inmagene Site 23 Los Angeles California
Inmagene Site 19 Ocala Florida
Inmagene Site 4 Tampa Florida
Inmagene Site 2 Rolling Meadows Illinois
Inmagene Site 6 Kew Gardens New York
Inmagene Site 21 New York New York
Inmagene Site 11 Woodbury New York
Inmagene Site 20 Charlotte North Carolina
Inmagene Site 10 Fargo North Dakota
Inmagene Site 9 Columbus Ohio
Inmagene Site 5 Mayfield Heights Ohio
Inmagene Site 3 Portland Oregon
Inmagene Site 12 Anderson South Carolina
Inmagene Site 8 Southlake Texas
Inmagene Site 7 Burien Washington
Inmagene Site 15 Surrey British Columbia
Inmagene Site 22 Vancouver British Columbia
Inmagene Site 17 Greater Sudbury Ontario
Inmagene Site 13 Mississauga Ontario
Inmagene Site 18 North Bay Ontario
Inmagene Site 14 Montreal Quebec
Inmagene Site 16 Saskatoon Saskatchewan

More Inmagene LLC trials in the USA

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis Recruiting

Other trials for the same condition

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis Active, not recruiting
Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials Starting soon
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema Recruiting
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis Active, not recruiting
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07734415 on ClinicalTrials.gov ↗ ← All trials in the USA